Therapeutic Vaccine Market - Growth, Trends, and Forecast (2020 - 2025)

The Therapeutic Vaccine Market is segmented by Products, Technology, and Geography

Market Snapshot

Study Period:

2016-2024

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

Major Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

 

 

Global Therapeutic Vaccine market is expected to witness a CAGR of 12.63%, during the forecast period. Certain factors that are driving the market growth include favorable government funding for vaccine development, rising prevalence of diseases, and an increase in R&D expenditure of the companies.

 

  • Increased awareness regarding the potential value of vaccination in the developed, developing, and under-developed regions of the world. Major governmental and humanitarian organizations have taken up an active interest in curbing the diseases prevented by vaccines and vaccinating the maximum number of infants and adults as possible, which led to the adoption of new production and supply strategies and the formation of the donor market, that accounts for the biggest market for vaccines, in terms of dosage, globally. 

 

  • To achieve the full potential of science and technology and prevent the onset of diseases in the population (especially children), various regional Governments have established agreements and partnerships with several organizations to initiate/ improve the already existing R&D schemes to prevent any future onset disease outbreak.

 

  • However, there is one drawback in this scenario. Similar to drug production, R&D of vaccine takes a long period, and it requires huge investments. Vaccines have to undergo clinical trials before they obtain approval for commercial release.

 

  • At each stage of the clinical trial, the majority of the vaccines are rejected. By the time the final product is approved for commercial use, there is a humongous capital spent on the R&D process of vaccine development. This huge capital expenditure has an indirect effect on the final pricing of the product. The product becomes expensive in some instances, which is not affordable to a significant chunk of the population, especially in the third world regions where the per capita income is significantly lower.

Scope of the Report

A therapeutic vaccine is applied after infection occurs, in order, to induce antiviral immunity to alter the course of the disease.  In other words, therapeutic vaccines help teach the body how to do a better job of protecting itself.

Products
Autoimmune Disease Vaccines
Neurological Disease Vaccines
Cancer Vaccines
Infectious Disease Vaccines
Other Products
Technology
Allogeneic Vaccine
Autologous Vaccine
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Autoimmune Disease Vaccines is Expected to Hold Significant Market Share

Autoimmune diseases are those, which occur when the body’s immune system attacks and destroys healthy tissues of the body by mistake. An autoimmune disorder can lead to the growth of a tumor, damage healthy tissues, and cause changes in the function of a specific organ.  Autoimmune diseases can affect blood vessels, connective tissues, endocrine glands, joints, muscles, red blood cells, skin, etc. Autoimmune diseases are among the top ten leading causes for death among women in all age groups, spanning to those up to 65 years. A substantial minority of the population suffers from these diseases, which are attenuating, chronic, and fatal. The development of vaccines for different types of autoimmune diseases is underway.

To understand key trends, Download Sample Report

North America Dominates the Market and Expected to do Same in the Forecast Period

The United States is the largest market in North America, which accounts for about 78% of the total market volume. Canadian and Mexican markets have high growth potentials, and the US market is focused on the invention and development of new vaccines. The demand for better and more efficient vaccines is expected to increase, which may reduce the shortfall of vaccines, during disease outbreaks. For example, the demand for the measles vaccines has increased drastically, due to the worst measles outbreak in North America over the past 15 years.

To understand geography trends, Download Sample Report.

Competitive Landscape

The Therapeutic Vaccine market is highly competitive and consists of a number of major players. Companies like Agenus Inc., Argos Therapeutic Inc., Celldex Therapeutic Inc., Cytos Biotechnology AG, Dendreon Corp, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, Vaccinogen Inc., among others, hold the substantial market share in the Therapeutic Vaccine market.

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Favorable Government Funding For Vaccine Development

      2. 4.2.2 Rising Prevalence of Diseases

      3. 4.2.3 Increase in R&D Expenditure by the Companies

    3. 4.3 Market Restraints

      1. 4.3.1 Huge Capital Expenditures

      2. 4.3.2 Stringent Regulatory Framework

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Products

      1. 5.1.1 Autoimmune Disease Vaccines

      2. 5.1.2 Neurological Disease Vaccines

      3. 5.1.3 Cancer Vaccines

      4. 5.1.4 Infectious Disease Vaccines

      5. 5.1.5 Other Products

    2. 5.2 Technology

      1. 5.2.1 Allogeneic Vaccine

      2. 5.2.2 Autologous Vaccine

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Agenus Inc.

      2. 6.1.2 Argos Therapeutic Inc.

      3. 6.1.3 Celldex Therapeutic Inc.

      4. 6.1.4 Cytos Biotechnology AG

      5. 6.1.5 Dendreon Corp

      6. 6.1.6 GlaxoSmithKline

      7. 6.1.7 Merck & Co.

      8. 6.1.8 Novartis

      9. 6.1.9 Pfizer

      10. 6.1.10 Vaccinogen Inc.

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

** Subject to Availability

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

Related Reports